bpc-157 legal status us fda 2025 or 2026 Peptide FDA to Reconsider BPC-157 and
Description
While human clinical trials are still needed, the preclinical evidence is compelling
Severe side effects include an increased risk of diabetes and certain cancers
The SCFAs can interact with many receptors to enhance immune-signaling and anti-inflammatory activities
No BPC-157 and TB-500 are mechanistically unrelated
